MX2013003152A - Composiciones de bepotastina. - Google Patents

Composiciones de bepotastina.

Info

Publication number
MX2013003152A
MX2013003152A MX2013003152A MX2013003152A MX2013003152A MX 2013003152 A MX2013003152 A MX 2013003152A MX 2013003152 A MX2013003152 A MX 2013003152A MX 2013003152 A MX2013003152 A MX 2013003152A MX 2013003152 A MX2013003152 A MX 2013003152A
Authority
MX
Mexico
Prior art keywords
compositions
bepotastine
compositions including
bepotastine compositions
sorbitol
Prior art date
Application number
MX2013003152A
Other languages
English (en)
Other versions
MX341109B (es
Inventor
Angel Padilla
George Baklayan
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2013003152A publication Critical patent/MX2013003152A/es
Publication of MX341109B publication Critical patent/MX341109B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan composiciones nuevas que incluyen besilato de bepotastina tales como composiciones libres de sorbitol, composiciones que incluyen por lo menos aproximadamente 0.008% peso/volumen de cloruro de benzalconio, y composiciones que incluyen hidroxipropil celulosa E15 LV.
MX2013003152A 2010-10-06 2011-10-06 Composiciones de bepotastina. MX341109B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39026210P 2010-10-06 2010-10-06
PCT/US2011/055011 WO2012048059A2 (en) 2010-10-06 2011-10-06 Bepotastine compositions

Publications (2)

Publication Number Publication Date
MX2013003152A true MX2013003152A (es) 2013-08-15
MX341109B MX341109B (es) 2016-08-09

Family

ID=45928420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003152A MX341109B (es) 2010-10-06 2011-10-06 Composiciones de bepotastina.

Country Status (12)

Country Link
US (2) US20130046240A1 (es)
EP (1) EP2624836B1 (es)
JP (1) JP5759553B2 (es)
KR (1) KR20130099140A (es)
CN (1) CN103260623B (es)
BR (1) BR112013008244A8 (es)
CA (1) CA2813748C (es)
ES (1) ES2551752T3 (es)
HU (1) HUE026106T2 (es)
MX (1) MX341109B (es)
PL (1) PL2624836T3 (es)
WO (1) WO2012048059A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012094283A2 (en) * 2011-01-04 2012-07-12 Ista Pharmaceuticals, Inc. Bepotastine compositions
KR101427611B1 (ko) * 2011-03-08 2014-08-11 롬엔드하스전자재료코리아유한회사 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
KR20120109744A (ko) * 2011-03-25 2012-10-09 롬엔드하스전자재료코리아유한회사 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
US20140171794A1 (en) * 2012-12-13 2014-06-19 James Liu Method of a Liquid Surgery
CN103755626A (zh) * 2014-01-23 2014-04-30 安徽安腾药业有限责任公司 一种贝托斯汀关键中间体的合成方法
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR20190049023A (ko) * 2017-11-01 2019-05-09 (주)아이엠디팜 베포타스틴 또는 이의 약학적으로 허용가능한 염을 포함하는 방출제어 단일 매트릭스 정제 및 이의 제조방법
CN112121013B (zh) * 2020-10-23 2022-10-28 南京科默生物医药有限公司 一种药物组合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8902300D0 (en) * 1989-02-02 1989-03-22 Bryce Smith Derek Antirhinoviral preparations
CN1222852A (zh) * 1996-06-04 1999-07-14 普罗克特和甘保尔公司 含鼻内类固醇和抗组胺剂的鼻喷雾剂
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
US8784789B2 (en) * 2002-07-31 2014-07-22 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
PL373433A1 (en) * 2002-08-30 2005-08-22 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US7188231B2 (en) * 2003-06-30 2007-03-06 Intel Corporation Multimedia address generator
DK2486942T3 (en) * 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
BRPI0615032A2 (pt) * 2005-09-01 2011-04-26 Biolipox Ab composição farmacêutica, processo para a preparação da mesma, e, uso de uma composição
KR100878698B1 (ko) * 2007-04-05 2009-01-13 한미약품 주식회사 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
RU2009141592A (ru) * 2007-04-11 2011-05-20 Алькон Рисерч, Лтд. (Us) ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US7707534B2 (en) * 2007-07-25 2010-04-27 Dell Products, Lp Circuit board design tool and methods
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
JP2009263298A (ja) * 2008-04-28 2009-11-12 Ss Pharmaceut Co Ltd 不快な味を隠ぺいした経口組成物
JP2012501315A (ja) * 2008-09-02 2012-01-19 グラクソ グループ リミテッド 鼻炎を治療するためのｔｒｐｖｌアンタゴニストｓｂ−７０５４９８
JP2010195716A (ja) * 2009-02-25 2010-09-09 Takeda Chem Ind Ltd 点鼻睡眠導入剤
WO2012094283A2 (en) * 2011-01-04 2012-07-12 Ista Pharmaceuticals, Inc. Bepotastine compositions

Also Published As

Publication number Publication date
BR112013008244A8 (pt) 2018-02-14
JP2013539758A (ja) 2013-10-28
US20120225905A1 (en) 2012-09-06
EP2624836A2 (en) 2013-08-14
KR20130099140A (ko) 2013-09-05
MX341109B (es) 2016-08-09
CN103260623B (zh) 2016-11-02
US20130046240A1 (en) 2013-02-21
WO2012048059A3 (en) 2012-05-31
BR112013008244A2 (pt) 2017-12-05
ES2551752T3 (es) 2015-11-23
CA2813748C (en) 2016-06-14
WO2012048059A2 (en) 2012-04-12
JP5759553B2 (ja) 2015-08-05
CN103260623A (zh) 2013-08-21
EP2624836B1 (en) 2015-09-23
HUE026106T2 (en) 2016-05-30
PL2624836T3 (pl) 2016-04-29
EP2624836A4 (en) 2014-05-14
CA2813748A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
MX2013007409A (es) Composiciones de bepotastina.
MX341109B (es) Composiciones de bepotastina.
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
CA2865011C (en) Methods and compositions for treating huntington's disease
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
IN2012DN02702A (es)
IN2012DN02177A (es)
IN2012DN00754A (es)
MX2013011054A (es) Antagonistas de trpvi.
MY153915A (en) Organic compounds
TN2011000172A1 (en) Therapeutic antiviral peptides
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
MX346980B (es) Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona.
PH12015501146A1 (en) Hydantoin derivative
MX2010005105A (es) Ciclopentanos substituidos que comprenden actividad de prostaglandina.
MX2012007837A (es) Derivados de oxazolopirimidina 2, 5 - sustituidos.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2016005160A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.

Legal Events

Date Code Title Description
FG Grant or registration